疑难病杂志
疑難病雜誌
의난병잡지
JOURNAL OF DIFFICULT AND COMPLICATED CASES
2015年
5期
480-482,486
,共4页
李伟%张海燕%宋霆婷%胡芳娟
李偉%張海燕%宋霆婷%鬍芳娟
리위%장해연%송정정%호방연
肺癌脑转移%靶向给药%同步放化疗%临床效果%安全性
肺癌腦轉移%靶嚮給藥%同步放化療%臨床效果%安全性
폐암뇌전이%파향급약%동보방화료%림상효과%안전성
Brain metastasis of lung cancer%Target drug therapy%Concurrent chemotherapy%Clinical effect%Safety
目的：探讨肺癌脑转移患者采用靶向药物治疗联合同步放化疗的临床效果及安全性。方法2010年1月—2012年6月收治肺癌脑转移患者66例，采用随机数字表法分为联合组和对照组各33例，对照组采用全脑同步放疗结合同步化疗，联合组在对照组基础上采用靶向药物治疗，比较2组患者的近期疗效、远期预后及不良反应情况。结果联合组的近期疗效显著优于对照组（ Z ＝－2．501， P ＝0．012）；联合组的总有效率为93．94％，高于对照组的81．82％，但差异不显著（χ2＝2．276， P ＝0．131）。联合组的无疾病进展生存中位时间为8．0个月，显著长于对照组的5．0个月（χ2＝10．742， P ＝0．001）；联合组的2年生存率为36．36％，对照组的2年生存率为27．27％，比较差异无统计学意义（χ2＝0．629， P ＝0．428）；联合组的总生存中位时间为16．0个月，显著长于对照组的9．0个月（χ2＝4．054， P ＝0．044）；联合组和对照组各种不良反应的发生率比较差异均无统计学意义（ P ＞0．05）。结论肺癌脑转移患者采用靶向药物治疗联合同步放化疗治疗对延长患者的无疾病进展生存期、总生存时间及近期疗效具有积极意义。
目的：探討肺癌腦轉移患者採用靶嚮藥物治療聯閤同步放化療的臨床效果及安全性。方法2010年1月—2012年6月收治肺癌腦轉移患者66例，採用隨機數字錶法分為聯閤組和對照組各33例，對照組採用全腦同步放療結閤同步化療，聯閤組在對照組基礎上採用靶嚮藥物治療，比較2組患者的近期療效、遠期預後及不良反應情況。結果聯閤組的近期療效顯著優于對照組（ Z ＝－2．501， P ＝0．012）；聯閤組的總有效率為93．94％，高于對照組的81．82％，但差異不顯著（χ2＝2．276， P ＝0．131）。聯閤組的無疾病進展生存中位時間為8．0箇月，顯著長于對照組的5．0箇月（χ2＝10．742， P ＝0．001）；聯閤組的2年生存率為36．36％，對照組的2年生存率為27．27％，比較差異無統計學意義（χ2＝0．629， P ＝0．428）；聯閤組的總生存中位時間為16．0箇月，顯著長于對照組的9．0箇月（χ2＝4．054， P ＝0．044）；聯閤組和對照組各種不良反應的髮生率比較差異均無統計學意義（ P ＞0．05）。結論肺癌腦轉移患者採用靶嚮藥物治療聯閤同步放化療治療對延長患者的無疾病進展生存期、總生存時間及近期療效具有積極意義。
목적：탐토폐암뇌전이환자채용파향약물치료연합동보방화료적림상효과급안전성。방법2010년1월—2012년6월수치폐암뇌전이환자66례，채용수궤수자표법분위연합조화대조조각33례，대조조채용전뇌동보방료결합동보화료，연합조재대조조기출상채용파향약물치료，비교2조환자적근기료효、원기예후급불량반응정황。결과연합조적근기료효현저우우대조조（ Z ＝－2．501， P ＝0．012）；연합조적총유효솔위93．94％，고우대조조적81．82％，단차이불현저（χ2＝2．276， P ＝0．131）。연합조적무질병진전생존중위시간위8．0개월，현저장우대조조적5．0개월（χ2＝10．742， P ＝0．001）；연합조적2년생존솔위36．36％，대조조적2년생존솔위27．27％，비교차이무통계학의의（χ2＝0．629， P ＝0．428）；연합조적총생존중위시간위16．0개월，현저장우대조조적9．0개월（χ2＝4．054， P ＝0．044）；연합조화대조조각충불량반응적발생솔비교차이균무통계학의의（ P ＞0．05）。결론폐암뇌전이환자채용파향약물치료연합동보방화료치료대연장환자적무질병진전생존기、총생존시간급근기료효구유적겁의의。
Objective To investigate the clinical effect and safety of target drug therapy combined with synchronous radiotherapy and chemotherapy in treatment of brain metastases from lung cancer.Methods From 2010 January to 2012 June, 66 cases of brain metastases origin from lung cancer patients were enrolled, using random number table, they were di-vided into combination group and control group with 33 cases in each group, the control group treated with whole brain radio-therapy, combined with synchronous chemotherapy, combination group based on the therapy of control group, also treated with target drug therapy, long term prognosis and adverse reaction were compared between the two groups of patients.Results The short term efficacy of combined group was significantly better than the control group ( Z =-2.501, P =0.012);combi-nation groupˊs total effectiveness was 93.94%, which was higher than that of the control group(81.82%) , but the difference was not significant (χ2 =2.276, P =0.131).The combination group’s median disease free survival was 8.0 months, which was longer than 5.0 months in the control group (χ2 =10.742, P =0.001);the 2 year survival rate was 36.36%in combi-nation group, control group’s 2 years survival rate was 27.27%, 2 years survival rate revealed no significant difference be-tween the two groups of patients (χ2 =0.629, P =0.428); overall survival in the combination group showed a median of 16.0 months, which was longer than 9.0 months in the control group (χ2 =4.054, P =0.044);combination group and the control group’s incidence of adverse reaction revealed no significant differences ( P <0.05).Conclusion Patients with tar-get drug therapy combined with radiotherapy and chemotherapy has positive significance to the progression of free survival, o-verall survival and efficacy for patients with brain metastasis from lung cancer.
